Smith Eric E, Schwamm Lee H
From the Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Canada (E.E.S.); and Stroke Service, Department of Neurology, Massachusetts General Hospital, Boston (L.H.S.).
Stroke. 2015 Jun;46(6):1462-7. doi: 10.1161/STROKEAHA.115.008385. Epub 2015 May 5.
Endovascular acute ischemic stroke therapy is now proven by randomized controlled trials to produce large, clinically meaningful benefits. In response, stroke systems of care must change to increase timely and equitable access to this therapy. In this review, we provide a North American perspective on implications for stroke systems, focusing on the United States and Canada, accompanied by initial recommendations for changes. Most urgently, every community must create access to a hospital that can safely and quickly provide intravenous tissue-type plasminogen activator and immediately transfer appropriate patients onward to a more capable center as required. Safe and effective therapy in the community setting will be ensured by certification programs, performance measurement, and data entry into registries.
随机对照试验现已证明血管内急性缺血性中风治疗能产生巨大的、具有临床意义的益处。对此,中风护理系统必须做出改变,以增加及时、公平地获得这种治疗的机会。在本综述中,我们从北美视角探讨对中风系统的影响,重点关注美国和加拿大,并给出初步的变革建议。最紧迫的是,每个社区都必须确保有一家医院能够安全、快速地提供静脉注射组织型纤溶酶原激活剂,并根据需要立即将合适的患者转送到更有能力的中心。通过认证项目、绩效评估以及将数据录入登记系统,将确保在社区环境中进行安全有效的治疗。